Peripheral Opioid Antagonists Inhibit Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer using opioid agonists, such as morphine, can stimulate endothelial cell proliferation and angiogenesis, potentially hastening tumor progression due to side effects like nausea and immunosuppression, and existing opioid antagonists have unclear anticancer effects unrelated to angiogenesis.
Innovation Solution
Administering peripheral opioid antagonists, like methylnaltrexone, to inhibit endothelial cell migration and proliferation associated with angiogenesis, either alone or in combination with anticancer agents, to attenuate tumor growth and metastasis by targeting the formation of new blood vessels rather than the tumor cells themselves.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If opioid agonists (e.g., morphine) are used to treat cancer pain, then pain relief is achieved, but endothelial cell proliferation and angiogenesis are stimulated, potentially hastening tumor progression
Solution Approach 1:
The invention segments the opioid receptor system into central and peripheral components. By using peripherally-acting opioid antagonists that do not cross the blood-brain barrier, the treatment selectively blocks peripheral opioid effects (including angiogenesis) while preserving central analgesic effects, thus resolving the contradiction between pain relief and tumor progression
Solution Approach 2:
The invention introduces peripherally-acting opioid antagonists as intermediary substances that mediate between opioid agonist therapy and its adverse effects. These antagonists act as selective blockers at peripheral opioid receptors, preventing the pro-angiogenic effects of opioids without interfering with their central pain-relieving effects
2Reliability
If conventional opioid antagonists are used, then opioid side effects are blocked, but their anticancer effects are unclear and may be unrelated to angiogenesis
Solution Approach 1:
The invention applies local quality by designing antagonists with selective distribution properties. Peripherally-acting antagonists concentrate their effect at peripheral opioid receptors in tissues including tumor vasculature, while having minimal presence in the central nervous system. This localized action provides clear mechanistic evidence for anti-angiogenic effects without the complexity of central nervous system interactions
3Productivity
If opioid agonists stimulate endothelial cell proliferation, then angiogenesis occurs, but this may support tumor growth beyond 2-3 mm diameter
Solution Approach 1:
The invention applies preliminary anti-action by administering peripherally-acting opioid antagonists to preemptively block opioid-induced angiogenesis before it can support significant tumor growth. By preventing the formation of new blood vessels that would enable tumors to grow beyond 2-3 mm, the treatment stops the pro-growth process in advance
Data Source
AI summary
The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.